Anticonvulsant Pharmacology in Epileptic Disorders
Summary
Epileptic disorders arise from aberrant, synchronous neuronal discharges leading to recurrent seizures that impose significant morbidity worldwide. The pharmacological management of epilepsy centres on antiseizure drugs (ASDs) that modulate ion channels, enhance inhibitory γ-aminobutyric acid (GABA)-mediated signalling or attenuate excitatory glutamatergic transmission. Advances in molecular pharmacology have elucidated diverse targets beyond traditional voltage-gated sodium and calcium channels, including specific subtypes of GABAA receptors, potassium conductances and synaptic vesicle proteins. Novel agents aim to overcome pharmacoresistance through multi-modal mechanisms, improved blood–brain barrier penetration and reduced systemic adverse effects. Integrative strategies—combining synthetic small molecules with natural products or adjunctive therapies—seek to optimise seizure control while preserving cognitive function. A deeper understanding of pathophysiological processes such as neuroinflammation and oxidative stress has further guided the rational design of anticonvulsant compounds with disease-modifying potential.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Anticonvulsant Pharmacology in Epileptic Disorders publication trend
The graph below shows the total number of articles in anticonvulsant pharmacology in epileptic disorders across all publications each year (not limited to Nature Index journals).
Technical terms
GABAergic neurotransmission: Inhibitory signalling mediated by γ-aminobutyric acid, primarily through GABAA and GABAB receptors.
Voltage-gated ion channel: Membrane proteins that open or close in response to changes in electrical potential, governing neuronal excitability.
Pharmacoresistance: Failure to achieve seizure control despite adequate trials of two or more appropriately chosen ASDs.
Neuroinflammation: Activation of central immune pathways, including microglial and astrocytic responses, contributing to epileptogenesis and seizure propagation.
Antiseizure drug (ASD): A pharmacological agent designed to prevent or reduce the frequency and severity of epileptic seizures.
References
- Ameliorative Potential of (-) Pseudosemiglabrin in Mice with Pilocarpine-Induced Epilepsy: Antioxidant, Anti-Inflammatory, Anti-Apoptotic, and Neurotransmission Modulation. International Journal of Molecular Sciences (2023).
- Phytotherapeutic options for the treatment of epilepsy: pharmacology, targets, and mechanism of action. Frontiers in Pharmacology (2024).
- Natural Medicines for the Treatment of Epilepsy: Bioactive Components, Pharmacology and Mechanism. Frontiers in Pharmacology (2021).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.